LITTLETON, Mass.--(BUSINESS WIRE)--Mevion Medical Systems is announcing the Los Angeles Proton Center is building a three-room MEVION S250mx Proton Therapy System. The system will include Mevion’s HYPERSCAN pencil beam scanning technology and will be installed near Los Angeles, in the city of Montebello, on the campus of Beverly Hospital. The installation will take place in phases, with the first of the three rooms treating cancer patients in late 2017.
“The MEVION S250mx was the optimal solution for our facility because it allows for a flexible, phased installation,” said Charles Liu, president of the Los Angeles Proton Center. “Just as importantly, we continue to be impressed with the proven results of all of Mevion’s clinically operational systems, including Mevion’s industry-leading ramp up time, high patient throughput, and low staffing and maintenance requirements. The decision to select Mevion and its product solutions will allow us to consistently provide high-quality proton therapy to a large number of patients.”
The MEVION S250mx is the fully scalable version of Mevion’s revolutionary proton therapy technology and is available in two, three or four room configurations. Each room is fully independent, with its own proton accelerator, providing inherent redundancy and 100 percent facility uptime 365 days per year.
“The MEVION S250mx is unique in the industry because it allows cancer centers to phase-in the installation of a multi-room system as their patient volume increases. By adding one room at a time, initial cash flow demands are lower and financial risk is reduced,” said Joseph K. Jachinowski, president and CEO of Mevion Medical Systems.
The Los Angeles Proton Center is an independent proton center that will collaborate with renowned cancer specialists to treat adult and pediatric cancer patients from the Greater Los Angeles area. The center will also serve international patients who are seeking cancer care on the West Coast of the United States.
Similar Mevion systems have ramped up to full capacity in as little as three months and achieved an annualized rate of 350 patients per room, per year. That is more than 25 percent better than the average U.S. proton therapy center.
The Los Angeles system is the third system purchase announced by Mevion in the past six weeks. In October, Mevion announced the installation of a MEVION S250 to Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, Switzerland, and a MEVION S250i with HYPERSCAN to the Ackerman Cancer Center in Jacksonville, Florida.
About Mevion Medical Systems
Mevion Medical Systems, Inc. is a leading provider of high-quality proton therapy systems for use in radiation treatment for cancer patients. Mevion is privately held and based in Littleton, Massachusetts, with international offices in the United Kingdom and Japan and a joint venture in China. For more information, please visit www.mevion.com.
About the MEVION S250 Series
The MEVION S250 Series is elegantly designed to deliver high-powered, efficient proton therapy treatments. Built upon the world’s only gantry-mounted proton accelerator and benefiting from Mevion’s patented direct beam technology, the MEVION S250 Series delivers on the therapeutic promise of proton therapy while enhancing beam quality, stability and uptime. The result is reduced system complexity, higher reliability and throughput, and lower capital and operating costs—making the MEVION S250 Series a compelling, financially viable solution for all cancer centers. The series is comprised of:
- MEVION S250, offering highly stable, next-generation volumetric delivery capabilities
- MEVION S250i with HYPERSCAN technology, overcoming pencil beam scanning uncertainties by delivering robust Intensity Modulated Proton Therapy treatment at hyper-speed
- MEVION S250mx, making proton therapy fully scalable, with two, three and four room designs that are inherently redundant and guarantee 100 percent facility uptime
HYPERSCAN has not been cleared by the USFDA for clinical use.